DESADENOSINE

USPTO USPTO 2000 CANCELLED - SECTION 8

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The US trademark DESADENOSINE was filed as Word mark on 08/16/2000 at the U.S. Patent and Trademark Office.
It was registered as a trademark on 01/07/2003. The current status of the mark is "CANCELLED - SECTION 8".

Trademark Details Last update: May 16, 2018

Trademark form Word mark
File reference 76113583
Register number 2670996
Application date August 16, 2000
Publication date October 15, 2002
Entry date January 7, 2003

Trademark owner

7 Clarke Drive
08512 Cranbury
US

Trademark representatives

goods and services

5 Describing and providing medical diagnostic and pharmaceutical preparations with nucleotide sequences that have a low content of, or fully lack, adenosine, for testing, preventing, and therapeutically treating human and non-human animal respiratory ailments that may be associated with hyper-sensitivity or hyper-responsiveness to adenosine, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in many cases are adenosine receptor associated symptoms; pharmaceutical preparations for the treatment of airway and pulmonary diseases and conditions, such as asthma, pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, Acute Respiratory Distress Syndrome (ARDS), renal damage and failure, ischemia, resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating SupraVentricular Tachycardia (SVT), adenosine stress tests, infantile Respiratory Distress Syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vascoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, e.g., colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, etc., as well as all other metastatic cancers, e.g., cancers which metastasized to the lung(s), breast, liver and prostate

ID: 1376113583